Long Zone Holdings Inc. Buys 10,000 Shares of Knight Therapeutics Inc (TSE:GUD) Stock

Knight Therapeutics Inc (TSE:GUD) insider Long Zone Holdings Inc. bought 10,000 shares of the firm’s stock in a transaction dated Tuesday, May 21st. The shares were acquired at an average price of C$7.39 per share, with a total value of C$73,900.00. Following the completion of the transaction, the insider now owns 21,621,433 shares of the company’s stock, valued at approximately C$159,782,389.87.

Shares of TSE:GUD opened at C$7.77 on Thursday. Knight Therapeutics Inc has a 52-week low of C$7.10 and a 52-week high of C$8.81. The firm has a market capitalization of $1.06 billion and a price-to-earnings ratio of 49.81. The company has a debt-to-equity ratio of 0.10, a current ratio of 32.29 and a quick ratio of 31.73.

Knight Therapeutics (TSE:GUD) last announced its quarterly earnings results on Thursday, May 9th. The company reported C$0.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of C$0.03 by C$0.01. The business had revenue of C$2.96 million during the quarter, compared to analyst estimates of C$3.06 million. As a group, equities analysts expect that Knight Therapeutics Inc will post 0.17 earnings per share for the current fiscal year.

Separately, Raymond James reiterated an “outperform” rating and issued a C$10.25 target price on shares of Knight Therapeutics in a research note on Wednesday, May 8th.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Sundance Herald and is the property of of Sundance Herald. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://sundanceherald.com/2019/06/13/insider-buying-knight-therapeutics-inc-gud-insider-acquires-10000-shares-of-stock.html.

Knight Therapeutics Company Profile

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Read More: Back-End Load

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply